论文部分内容阅读
通常烷化剂不同时应用。然而,有些烷化剂其主要作用机理和作用部位不同,因此,当这些烷化剂联合应用时有其治疗价值。环磷酰胺(CTX)和异环磷酰胺(ifosfamide)对非小细胞性肺癌(NSCLC)是最有效的两种药物。这两种烷化剂经肝脏活化后产生代谢产物的比率不同,烷基部分的作用点亦不同,相互作用在DNA的不同部位。CTX和异环磷酰胺在临床上无交叉耐药现象,并有不同的毒副作用,作者总结了CTX和异环磷酰胺联用对晚期NSCLC的作用和毒性情况。
Usually alkylating agents are not applied at the same time. However, some alkylating agents have different main action mechanisms and site of action. Therefore, when these alkylating agents are used in combination, they have therapeutic value. Cyclophosphamide (CTX) and ifosfamide are the two most effective drugs for non-small cell lung cancer (NSCLC). The ratio of metabolites produced when these two alkylating agents are activated by the liver is different. The point of action of the alkyl moiety is also different and interacts with different parts of the DNA. CTX and ifosfamide have no clinical cross-resistance and have different toxic and side effects. The authors summarized the effects and toxicity of CTX and ifosfamide on advanced NSCLC.